AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
2026 Updates: What Cancer Doctors Are Saying About Ivermectin and Cancer Treatment
By The Cancer News Team
Oncologists explain why ivermectin is not a proven cancer treatment, summarizing current evidence, ongoing trials in TNBC, and how clinicians address patient misinformation.
2026 Updates: What Cancer Doctors Are Saying About Ivermectin and Cancer Treatment
By The Cancer News Team
Oncologists explain why ivermectin is not a proven cancer treatment, summarizing current evidence, ongoing trials in TNBC, and how clinicians address patient misinformation.
2026 Updates: What Cancer Doctors Are Saying About Ivermectin and Cancer Treatment
By The Cancer News Team
Oncologists explain why ivermectin is not a proven cancer treatment, summarizing current evidence, ongoing trials in TNBC, and how clinicians address patient misinformation.
Interpreting Bladder Cancer Abstracts at GU ASCO 2026 for Real-World Practice
By Jason Brown, MD, PhD
Expert commentary from a genitourinary oncologist on top research from ASCO Genitourinary Cancers Symposium
Interpreting Bladder Cancer Abstracts at GU ASCO 2026 for Real-World Practice
By Jason Brown, MD, PhD
Expert commentary from a genitourinary oncologist on top research from ASCO Genitourinary Cancers Symposium
Interpreting Bladder Cancer Abstracts at GU ASCO 2026 for Real-World Practice
By Jason Brown, MD, PhD
Expert commentary from a genitourinary oncologist on top research from ASCO Genitourinary Cancers Symposium
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
Frontline EGFR-Mutant NSCLC: Navigating an Era of Combination Therapy
By Angel Qin, MD
New frontline therapies are transforming EGFR-mutant NSCLC care. Learn how MARIPOSA, FLAURA2, and emerging biomarker-driven strategies are reshaping treatment selection and survival outcomes.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Top 5 Takeaways from Dr. Paolo Tarantino on the Future of Antibody-Drug Conjugates in Solid Oncology
By The Cancer News Team
Key insights from Dr. Paolo Tarantino on how antibody-drug conjugates are transforming solid tumor treatment, moving from late-line therapy to frontline and curative-intent strategies.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Antibody-Drug Conjugates in Solid Tumors: From Magic Bullet to Standard of Care
By Paolo Tarantino, MD, PhD
Antibody-drug conjugates (ADCs) are transforming cancer care by delivering targeted chemotherapy with improved efficacy across multiple solid tumors, redefining treatment from late-line therapy to frontline standard.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.
Dr. Hina Khan on Closing the Gap: Lung Cancer Screening Disparities and the Fight for Equitable Low-Dose CT Access
By Hina Khan, MD
Lung cancer screening saves lives, yet disparities persist. Dr. Hina Khan explores barriers to low-dose CT access and community-driven solutions to improve early detection and equity.
Real-World Impact: Applying SABCS 2025 Advances in Community Oncology
By Sara Zhukovsky, MD; Christos Vaklavas, MD
How SABCS 2025 advances are transforming community oncology, with practical strategies to improve breast cancer screening, treatment adherence, survivorship care, and equitable access.
Real-World Impact: Applying SABCS 2025 Advances in Community Oncology
By Sara Zhukovsky, MD; Christos Vaklavas, MD
How SABCS 2025 advances are transforming community oncology, with practical strategies to improve breast cancer screening, treatment adherence, survivorship care, and equitable access.
Real-World Impact: Applying SABCS 2025 Advances in Community Oncology
By Sara Zhukovsky, MD; Christos Vaklavas, MD
How SABCS 2025 advances are transforming community oncology, with practical strategies to improve breast cancer screening, treatment adherence, survivorship care, and equitable access.
Nonprofit Binaytara Awards $50,000 to Cancer Researchers in Inaugural Impact Pitch Competition
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
Nonprofit Binaytara Awards $50,000 to Cancer Researchers in Inaugural Impact Pitch Competition
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.
Nonprofit Binaytara Awards $50,000 to Cancer Researchers in Inaugural Impact Pitch Competition
By The Cancer News Team
Binaytara awards $50,000 in cancer research funding through its first-ever Impact Pitch, high-energy competition advancing innovative solutions for cancer health equity.